Early Vascular Adjustments to Prevent Preeclampsia

CompletedOBSERVATIONAL
Enrollment

314

Participants

Timeline

Start Date

November 1, 2014

Primary Completion Date

January 1, 2020

Study Completion Date

March 1, 2020

Conditions
PreeclampsiaSmall for Gestational Age at DeliveryHELLP Syndrome
Interventions
DRUG

tailored pharmaceutical treatment

Tailored medication is advised in women with inadequate hemodynamic adaptation to pregnancy. Type of medication depends on total peripheral vascular resistance and heart rate. In short, women with a low peripheral vascular resistance in parallel with a high heart rate are advised a betablocker (labetalol), while a vasodilating agent (calcium channel blocker, nifedipine) was advised in women with a high total peripheral vascular resistance in combination with a low heart rate. Women with suboptimal adaptation to pregnancy without an extreme pronounced vascular profile are advised a centrally acting sympatholytic agent (methyldopa).

Trial Locations (1)

Unknown

Maastricht UMC, Maastricht

All Listed Sponsors
lead

Maastricht University Medical Center

OTHER

NCT04216706 - Early Vascular Adjustments to Prevent Preeclampsia | Biotech Hunter | Biotech Hunter